Year: 2022
Type: article
Abstract: Assessment and treatment of Bone Marrow Lesions (BMLs) could ultimately make step changes to the lives of people with osteoarthritis (OA). We here review the imaging and pathological characteristics of OA-BMLs, their differential diagnosis and measurement, and cross-sectional and longitudinal associations with pain and OA structural progression. We discuss how biomechanical and cellular factors may contribute to BML pathogenesis, and how pharmacological and non-pharmacological interventions that target BMLs might reduce pain and OA structural progression. We critically appraise semiquantitative and quantitative methods for assessing BMLs, and their potential utilities for identifying people at risk of symptomatic and structural OA progression, and evaluating treatment responses. New interventions that target OA-BMLs should both confirm their importance, and reduce the unacceptable burden of OA.
Source: Osteoarthritis and Cartilage
Authors: D.A. Walsh, N. Sofat, A. Guermazi, D.J. Hunter
Institutions: University of Nottingham, Sherwood Forest Hospitals NHS Foundation Trust, Nottingham Biomedical Research Centre, St George's, University of London, St George’s University Hospitals NHS Foundation Trust, Boston University, VA Boston Healthcare System, The University of Sydney, Royal North Shore Hospital
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,590
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, School of Medicine, Boston University, Regeneron Pharmaceuticals, National Institute for Health and Care Excellence, UK Research and Innovation, University of Nottingham, Arthritis Australia, University of Sydney, Servier, Versus Arthritis, Merck Sharp and Dohme, National Health and Medical Research Council, UCB Pharma
OpenAlex ID: W4298112371